CareDx Inc. (CDNA)
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CareDx (CDNA) Q4 Earnings Miss Estimates
CareDx (CDNA) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CDNA shares climb after AlloHeme data show early AML/MDS relapse detection, backing its Transplant+ expansion into cell therapy markets.
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026
CareDx's President and CEO sold 19,480 shares over two days, totaling approximately $412,200 at an average price of $21.16 per share. The transaction reduced the CEO's direct holdings by 3.16%, leaving 597,405 shares directly owned post-sale.
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
CareDx (CDNA) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.14 per share a year ago.
CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant John Walter Hanna - President, CEO & Director Keith S. Kennedy - Chief Operating Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Tycho W.
Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
CareDx (CDNA) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago.
CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead
CareDx has a unique, comprehensive organ transplant diagnostics portfolio and maintains strong revenue growth, but faces intensifying competition and regulatory risks. Recent legal resolutions and operational improvements have strengthened the investment case, yet the company has never achieved operating profitability, raising concerns. Future growth depends on successful new product launches and expanding its ecosystem, but ongoing innovation is required to stay ahead of AI-driven competitors.
